Actively Recruiting
Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication
Led by Peking University First Hospital · Updated on 2026-04-30
70
Participants Needed
1
Research Sites
42 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To investigate the efficacy, safety, and compliance of a simplified strategy using vonoprazan plus clarithromycin for first-line treatment in patients with Helicobacter pylori infection, among those infected with strains without clarithromycin resistance gene mutations based on fecal clarithromycin resistance gene detection.
CONDITIONS
Official Title
Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18-70 years
- Positive 13C-urea breath test and fecal PCR confirming Helicobacter pylori infection
- Clinical indication for H. pylori eradication as judged by the physician
- No prior history of H. pylori eradication therapy
You will not qualify if you...
- Pregnant or lactating women
- History of allergy to drugs used in the eradication regimen
- Severe systemic diseases or malignant tumors
- History of gastric resection surgery
- Use of antibiotics or bismuth salts within 4 weeks
- Use of H2-receptor antagonists, proton pump inhibitors, or potassium-competitive acid blockers within 2 weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
Research Team
W
Weihong Wang, MD, PhD
CONTACT
M
Meng Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here